- Home
- MPU vs GTBP Comparison
MPU vs GTBP Comparison
Compare MPU & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPU | GTBP |
|---|---|---|
| Founded | 1989 | 1965 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 13.0M |
| IPO Year | 2023 | 2016 |
Fundamental Metrics
Financial Performance| Metric | MPU | GTBP |
|---|---|---|
| Price | $0.20 | $8.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 182.3K | ★ 410.6K |
| Earning Date | 04-16-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.22 |
| 52 Week High | $1.93 | $6.24 |
Technical Indicators
Market Signals| Indicator | MPU | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 39.37 | 95.15 |
| Support Level | $0.17 | $0.39 |
| Resistance Level | $0.25 | N/A |
| Average True Range (ATR) | 0.02 | 0.26 |
| MACD | 0.00 | 0.65 |
| Stochastic Oscillator | 25.79 | 85.83 |
Price Performance
Historical ComparisonAbout MPU Mega Matrix Corp.
Mega Matrix Inc is a holding company that offers investors an opportunity to participate in the growth of stablecoins, one of the fastest-evolving sectors in digital assets. The company generated revenue from the Membership and top-up streaming services revenue, Online advertising services, and Content licensing. Geographically, the company operates in the United States and Canada, Asia Pacific, Europe middle east and Africa, and Latin America.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.